Linee guida
Le vaccinazioni nei bambini oncoematologici
durante e dopo la chemioterapia
VACCINATIONS IN PAEDIATRIC CANCER PATIENTS DURING AND AFTER CHEMOTHERAPY
Gruppo di Lavoro Terapia di Supporto dell’Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP)
S. Cesaro1, S. Bezzio2, M. Giacchino2, A. Barone3, L. Battisti4, D. Caselli5, R. De Santis6, F. Fioredda7, S. Frenos5,
S. Livadiotti8, S. Marinello9, G.A. Zanazzo10
1SC Onco-Ematologia Pediatrica, Azienda Ospedaliero-Universitaria Integrata, Verona
2SC Onco-Ematologia Pediatrica, Azienda Ospedaliera OIRM - S. Anna, Torino
3SC Pediatria e Oncoematologia, Azienda Ospedaliera di Parma
4Dipartimento di Pediatria, Ospedale di Bolzano
5SC Onco-Ematologia Pediatrica, Ospedale Meyer, Firenze
6SC Onco-Ematologia Pediatrica, Ospedale “Casa Sollievo della Sofferenza”, S. Giovanni Rotondo (Foggia)
7Ematologia Pediatrica, Istituto “G. Gaslini”, Genova
8Immunologia Pediatrica e Malattie Infettive, Ospedale Bambino Gesù, Roma
9Divisione di Malattie Infettive, Azienda Ospedaliera di Padova
10SC Onco-Ematologia Pediatrica, IRCCS “Burlo Garofolo”, Trieste
Gennaio 2011 - pagg. 33 -38
Abstract
Aim - Defining the guidelines on vaccinations in paediatric cancer patients.
Method - We reviewed the literature published from 1980 to 2009 according to the
methodology suggested by the American Society of Infectious Disease. The intention was
to define recommendations on vaccinations in patients both during and after chemotherapy
as well as recommendation on vaccinations in family members. The conclusions
achieved were presented in 2 plenary discussion sessions before final approval. In case
of disagreement the issue was settled by discussion with an external expert.
Results - While on chemotherapy, the patient benefits HBV and influenza vaccinations.
During this phase, family members are advised to continue vaccinations as scheduled
by health plan or, if seronegative, vaccinations against varicella, measles, mumps, rubeola
are recommended. Although a reduction of serum antibody levels for vaccine-preventable
disease is reported following suspension of chemotherapy, the immunological
memory seems preserved. The response to booster is generally good, gives the patients
good protection and contributes to herd immunity.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Centres for Disease Control and Prevention
(CDC). Recommendations of the Advisory
Committee on Immunization Practices
(ACIP):General Recommendations on immunization.
MMWR 2006;55(NoRR-15).
2. Mustafa MM, Buchanan GR, Winick NJ.
Immune recovery in children with malignancy
after cessation of chemotherapy. J Ped
Hematol Oncol 1998;20:451-7.
3. Ek T, Mellander L, Andersson B, et al. Immune
reconstitution after childhood acute
lymphoblastic leukemia is most severely affected
in the high risk group. Ped Blood Cancer
2005;44:461-8.
4. Fioredda F, Cavillo M, Banov L, Plebani A,
Timitilli A, Castagnola E. Immunization after
the elective end of antineoplastic chemotherapy
in children. Pediatr Blood Cancer 2009;
52:165-8.
5. Recommendations of the Advisory Committee
on Immunization Practices (ACIP): use
of vaccines and immune globulins for persons
with altered immunocompetence. MMWR Recomm
Rep 1993;42(RR-4):1-18.
6. Royal College of Paediatrics and Child
Health Immunisation of the immunocompromised
child. Best Practice Statement London:
RCPCH,2002.www.rcpch.ac.UK.
7. Chisholm JC. Reimmunization after therapy
for childhood cancer. Clin Infect Dis 2007;44:
643-5.
8. Allen UD. Immunization for children with
cancer. Pediatr Blood Cancer 2007;49:1102-8.
9. Kish MA. Guide to development of practice
guidelines. Clin Infect Dis 2001;32:851-4.
10. Rautonen J, Siimes MA, Lundström U, et
al. Vaccination of children during treatment
for leukemia. Acta Paediatr Scand 1986;75:
579-85.
11. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson
J. Intensive treatment for childhood
acute lymphoblastic leukemia reduces immune
responses to diphtheria, tetanus, and Haemophilus
influenzae type b. J Pediatr Hematol
Oncol 2004;26:727-34.
12. Zengin E, Sarper N. Humoral immunity to
diphtheria, tetanus, measles and Haemophilus
influenzae type b in children with lymphoblastic
leukemia and response to re-vaccination.
Pediatr Blood Cancer 2009;53:967-72.
13. Emir S, Büyükpamuk M, Akyüz C, Kutluk
T, Güler E, Calar K. The comparison of antibody
response to different hepatitis B vaccines
with and without pre-S2 antigen in children
with cancer. Pediatr Hematol Oncol
2002;19:227-33.
14. Hovi L, Valle M, Siimes MA, Jalanko H,
Saarinen UM. Impaired response to hepatitis
B vaccine in children receiving anticancer
chemiotherapy. Pediatr Infect Dis J 1995;14:
931-5.
15. Koksal Y, Varan A, Aydin GB, et al. Comparison
of accelerated and rapid schedules for
monovalent hepatitis B and combined hepatitis
A/B vaccines in children with cancer. Pediatr
Hematol Oncol 2007;24:587-94.
16. Ramesh M, Marwaha RK, Chawla YK, Trehan
A. Seroconversion after Hepatitis B vaccination
in children receiving cancer chemotherapy.
Indian Pediatr 2000;37:882-6.
17. Yetgin S, Tavil B, Aytac S, Kuskonmaz B,
Karna G. Unexpected protection from infection
by two booster hepatitis B virus vaccination
in children with acute lymphoblastic
leukaemia. Leuk Res 2007;31:493-6.
18. Köksal Y, Yalcin B, Aydin GB, et al. Immunogenicity
of hepatitis A vaccine in children
with cancer. Pediatr Hematol Oncol
2006;23:619-24.
19. Bektas O, Karadeniz C, Oguz A,
Berberoglu S, Yilmaz N, Citak C. Assessment
of the immune response to trivalent split influenza
vaccine in children with solid tumors.
Pediatr Blood Cancer 2007;49:914-7.
20. Somjee S, Pai S, Parikh P, Banavali S,
Kelkar R, Advani S. Passive active prophylaxis
against Hepatitis B in children with acute
lymphoblastic leukaemia. Leuk Res 2002;26:
989-92.
21. Chisholm J, Howe K, Taj M, Zambon M.
Influenza immunisation in children with solid
tumours. Eur J Cancer 2005;41:2280-7.
22. Harper DM, Franco EL, Wheeler CM, et al.
Efficacy of a bivalent L1 virus-like particle vaccine
in prevention of infection with human papillomavirus
types 16 and 18 in young women:
a randomised controlled trial. Lancet 2004;
364:1757-65.
23. Chisholm JC, Devine T, Charlett A, Pinkerton
CR, Zambon M. Response to influenza immunisation
during treatment for cancer. Arch
Dis Child 2001;84:496-500.
24. Hsieh YC, Lu MY, Kao CL, et al. Response
to influenza vaccine in children with leukemia
undergoing chemotherapy. J Formos Med Assoc
2002;101:700-4.
25. Matsuzaki A, Suminoe A, Koga Y,
Kinukawa N, Kusuhara K, Hara T. Immune response
after influenza vaccination in children
with cancer. Pediatr Blood Cancer 2005;45:
831-7.
26. Porter CC, Edwards KM, Zhu Y, Frangoul
H. Immune responses to influenza immunization
in children receiving maintenance
chemotherapy for acute lymphoblastic leukemia.
Pediatr Blood Cancer 2004;42:36-40.
27. Shenep JL, Feldman S, Gigliotti F, et al. Response
of immunocompromised children with
solid tumors to a conjugate vaccine for
Haemophilus influenzae type b. J Pediatr 1994;
125:581-4.
28. Feldman S, Malone W, Wilbur R, Schiffman
G. Pneumococcal vaccination in children
with acute lymphocytic leukemia. Med Pediatr
Oncol 1985;13:69-72.
29. Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD. Immune response to conjugated
meningococcal C vaccine in pediatric
oncology patients. Pediatr Blood Cancer 2007;
49:918-23.
30. The Future II Study Group. Effect of prophylactic
human papillomavirus L1 virus-likeparticle
vaccine on risk of cervical intraepithelial
neoplasia grade 2, grade 3, and adenocarcinoma
in situ: a combined analysis of four randomised
clinical trials. Lancet 2007;369: 1861-8.
31. The Future II Study Group. Quadrivalent
vaccine against papillomavirus to prevent
high-grade cervical lesion. N Engl J Med
2007;356:1915-27.
32. Luthy KE, Tiedeman ME, Beckstrand RL,
Mills DA. Safety of live-virus vaccines for children
with immune deficiency. J Am Acad
Nurse Pract 2006;18:494-503.
33. Torigoe S, Hirai S, Oitani K, et al. Application
of live attenuated measles and mumps
vaccines in children with acute leukemia.
Biken J 1981;24:147-51.
34. Ercan TE, Soycan LY, Apak H, et al. Antibody
titers and immune response to diphtheria-
tetanus-pertussis and measles-mumpsrubella
vaccination in children treated for
acute lymphoblastic leukemia. J Pediatr Hematol
Oncol 2005;27:273-7.
35. Emir S, Büyükpamukçu M, Köseoglu V, et
al. Varicella vaccination in children with lymphoma
and solid tumours. Postgrad Med J
2006;82:760-2.
36. Leung TF, Li CK, Hung ECW, et al. Immunogenicity
of a two-dose regime of varicella
vaccine in children with cancers. Eur J
Haematol 2004;72:353-7.
37. Arbeter AM, Granowetter L, Starr S E,
Lange B, Wimmer R, Plotkin SA. Immunization
of children with acute lymphoblastic
leukemia with live attenuated varicella vaccine
without complete suspension of chemotherapy.
Pediatrics 1990;85:338-44.
38. LaRussa P, Steinberg S, Gershon AA. Varicella
vaccine for immunocompromised children:
results of collaborative studies in the
United States and Canada. J Infect Dis 1996;
174 (Suppl 3):S320-3.
39. Sartori AM. A review of the varicella vaccine
in immunocompromised individuals. Intern
J Infect Dis 2004;8:259-70.
40. Public Health Agency of Canada. Update
on Varicella. CCDR 2004:30. Disponibile su
http://www.phac-aspc.gc.ca/publicat/ccdrrmtc/
04vol30/acs-dcc-1/index-eng.php? success=
1.
41. Schrauder A, Gendo CH, Seidemann K, et al.
Varicella vaccination in a child with acute lymphoblastic
leukaemia. Lancet 2007;369: 1232.
42. American Academy of Pediatrics Immunization
in Special Clinical Circumstances. In:
Pickering LK, Baker CJ, Long SS, McMillan
JA (Eds). Red book: Report of the Committee
on Infectious Diseases, 28th edition. Elk
Grove Village, IL: American Academy of Pediatrics,
2009.
43. Feldman S, Andrew M, Norris M, McIntyre
B, Iyer R. Decline in rates of seropositivity
for measles, mumps, and rubella antibodies
among previously immunized children
treated for acute leukemia. Clin Infect Dis
1998;27:388-90.
44. Nilsson A, De Milito A, Engström P, et al.
Current chemotherapy protocols for childhood
acute lymphoblastic leukemia induce
loss of humoral immunity to viral vaccination
antigens. Pediatrics 2002;109:e91.
45. Reinhardt D, Houliara K, Pekrun A,
Lakomek M, Krone B. Impact of conventional
chemotherapy on levels of antibodies against
vaccine preventable diseases in children treated
for cancer. Scand J Infect Dis 2003;35:851-7.
46. van Tilburg CM, Sanders EA, Rovers MM,
Wolfs TF, Bierings MB. Loss of antibodies and
response to (re-)vaccination in children after
treatment for acute lymphocytic leukemia: a
systematic review. Leukemia 2006;20:1717-22.
47. van der Does A, Hermans J, Nagel J, van
Steenis G. Immunity to diphtheria, pertussis,
tetanus and poliomyelitis in children with
acute lymphocytic leukaemia after cessation
of chemotherapy. Pediatrics 1981;67:222-9.
48. von der Hardt K, Jungert J, Beck JD,
Heininger U. Humoral immunity against diphtheria,
tetanus and poliomyelitis after antineoplastic
therapy in children and adolescents-a
retrospective analysis. Vaccine 2000;18:2999-
3004.
49. Yu J, Chou AJ, Lennox A, et al. Loss of antibody
titers and effectiveness of revaccination
in post-chemotherapy pediatric sarcoma patients.
Pediatr Blood Cancer 2007;49:656-60.
50. Zignol M, Peracchi M, Tridello G, et al. Assessment
of humoral immunity to poliomyelitis,
tetanus, hepatitis B, measles,
rubella, and mumps in children after chemotherapy.
Cancer 2004;101:635-41.
51. Fioredda F, Plebani A, Hanau G, et al. Reimmunisation
schedule in leukaemic children
after intensive chemotherapy: a possible strategy.
Eur J Haematol 2005;74:20-3.
52. Patel SR, Ortín M, Cohen BJ, et al. Revaccination
of children after completion of standard
chemotherapy for acute leukemia. Clin
Infect Dis 2007;44:635-42.
53. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson
J. Avidity of tetanus and Hib antibodies
after childhood acute lymphoblastic
leukaemia: implications for vaccination strategies.
Acta Paediatr 2006;95:701-6.
54. Ercan TE, Soycan LY, Apak H, et al. Antibody
titers and immune response to diphtheria-
tetanus-pertussis and measles-mumpsrubella
vaccination in children treated for
acute lymphoblastic leukemia. J Pediatr Hematol
Oncol 2005;27:273-7.
55. Donaldson SS, Vosti KL, Berberich FR,
Cox RS, Kaplan HS, Schiffman G. Response to
pneumococcal vaccine among children with
Hodgkin’s disease. Rev Infect Dis 1981;3 Suppl:
S133-43.
56. Yu JW, Borkowski A, Danzig L, Reiter S,
Kavan P, Mazer BD. Immune response to conjugated
meningococcal C vaccine in pediatric
oncology patients. Pediatr Blood Cancer 2007;
49:918-23.
57. Lehrnbecher T, Schubert R, Behl M, et al.
Impaired pneumococcal immunity in children
after treatment for acute lymphoblastic
leukaemia. Br J Haematol 2009;147:700-5.
58. Yeung CY, Liang DC. Varicella vaccine in
children with acute lymphoblastic leukaemia
and non-Hodgkin lymphoma. Pediatr Hematol
Oncol 1992;9:29-34.
59. Esposito S, Cecinati V, Scicchitano B, et al.
Inpact of influenza-like illness and effectiveness
of influenza vaccinazion in oncohematological
children who have completed cancer
therapy. Vaccine 2010;28:1558-65.
60. Goosen Gm, Kremer LC, van de Wetwring
MD. Influenza vaccination in children being
treated with chemotherapy for cancer.
Cochrane Database Syst Rev 2009;(2):CD-
006484.
61. Klosky JL, Heather LG, Spunt SL, Randolph
ME, Green DM, Hudson MM. Human
papilloma vaccinazion in survivors of childhood
cancer. Cancer 2009;115:5627-36.
62. Shih YC, Pan IW. Influenza vaccinazion
among individual with cancer and their family
members. Am J Prev Med 2010;38:61-9.
63. Green book available at: http://webarchive.
nationalarchives.gov.uk/+/www.dh.
gov.uk/en/Publichealth/Healthprotection/I
mmunisation/Greenbook/DH_4097254.
64. Kappagoda C, Shaw PJ, Burgess MA,
Botham SJ, Cramer LD. Varicella vaccine in
non-immune household contacts of children
with cancer or leukaemia. J Paediatr Child
Health 1999;35:341-5.
65. Kamboj M, Sepkowitz KA. Risk of transmission
associated with live-attenuated vaccine
given to healthy persons caring for or residing
with an immunocompromised patient.
Infect Control Hosp Epidemiol 2007;28:702-7.
Corrispondenza: zanazzo@burlo.trieste.it